News | November 11, 2022
Jagsonpal Pharmaceuticals reports Q2FY23 net profit at Rs. 10.41 Cr
The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 61.64 crores during the period ended September 30, 2022.
Manish led SeQuent since 2014 and played a major role in transforming the company
The transaction as well as the open offer is expected to be completed by June this year.
Suvinys Developers will supply dydrogesterone to Jagsonpal Pharma as per the terms and conditions mentioned in the agreement.
Operating EBITDA grew by 82.7 % to Rs. 14.4 crore, EBITDA margin at 23.9%, and Profit After Tax (PAT) grew by 47.1% to Rs. 7.8 crore
Witnessing sizable consolidation (M& A) activity with Domestic Formulations and Hospitals being two areas wherein maximum M&A has occurred.
Subscribe To Our Newsletter & Stay Updated
